Complement-Based Drug Development Summit leaderboard
  • Tuesday, October 6, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 51

Eisai, Henlius Partner to Bring Serplulimab to Japan

Feb 6, 2026
Eisai Co., Ltd. and Shanghai Henlius Biotech have signed an exclusive commercialization and co-exclusive development and manufacturing licensing agreement for the anti-PD-1 antibody…
Read More...

Grünenthal, Apotex Sign Deal for Nebido Canada Rights

Feb 6, 2026
Grünenthal and Apotex Inc. have announced a new licensing agreement granting Apotex exclusive rights in Canada to Nebido (testosterone undecanoate), a long-acting injectable therapy…
Read More...

PrimeGen US Plans Nasdaq Listing via $1.5B SPAC Deal

Feb 5, 2026
PrimeGen US, a biotechnology company focused on regenerative medicine, has agreed to merge with special purpose acquisition company DT Cloud Star Acquisition Corporation in a…
Read More...

CEPI, Samsung Biologics Partner for Rapid Pandemic Vaccine Production

Feb 4, 2026
The Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with contract development and manufacturing organization Samsung Biologics to strengthen global readiness for…
Read More...

FDA Grants Breakthrough Status to Relay Breast Cancer Therapy

Feb 4, 2026
Relay Therapeutics has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for its investigational drug zovegalisib in combination with fulvestrant for…
Read More...

FDA Issues Complete Response Letter for Aquestive Allergy Film

Feb 3, 2026
Aquestive Therapeutics said the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for its New Drug Application seeking approval of Anaphylm, an…
Read More...

Genentech Licenses SanegeneBio RNAi Therapy in $1.5B Deal

Feb 3, 2026
SanegeneBio has entered a global licensing agreement with Genentech, part of the Roche Group, granting the pharmaceutical company exclusive worldwide rights to develop and commercialize…
Read More...

FDA Grants Breakthrough Status to Immix AL Amyloidosis Therapy

Jan 30, 2026
Immix Biopharma, Inc., a clinical-stage biotechnology company focused on developing therapies for difficult-to-treat diseases, has received a major regulatory boost after the U.S. Food…
Read More...

WuXi Biologics, Sinorda Partner on Bispecific Antibody for IBD

Jan 30, 2026
WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and manufacturing of SND006, a novel bispecific antibody being developed…
Read More...

Recordati, Moderna Partner on mRNA Therapy for Rare Metabolic Disease

Jan 30, 2026
Recordati has entered into a global collaboration and licensing agreement with Moderna to develop and commercialize mRNA-3927, an investigational mRNA-based therapy for the treatment of…
Read More...
Previous 1 … 49 50 51 52 53 … 956 Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Sanofi, Regeneron Expand Antibody Collaboration With $8B Deal
  • Abogen, Novartis Sign $7.2B RNA Therapeutics Deal
  • CAS, Novartis Partner on AI-Ready Reaction Data for Drug Discovery
  • SK pharmteco Invests $200M to Expand U.S. Drug Manufacturing
  • AstraZeneca Invests $2B in Summit Therapeutics for Cancer Research

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.